Clinical trials: Acute Myelogenous Leukemia
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior…
- Trial name
- NCT00373529
- Testing
- clofarabine
- Where
- 20 sites in United States
- Volunteers
- 116 people
- Sponsor
- Genzyme, a Sanofi Company
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
- Trial name
- PERSIST (NCT07474051)
- Testing
- UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123
- Where
- 5 sites in Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity.
- Trial name
- NCT07137637
- Testing
- HPB-092 tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Polymed Biopharmaceuticals, Inc.
Acute Leukemia, Myelodysplastic Syndromes
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT05170828
- Testing
- Cyclophosphamide, Fludarabine, Total Body Irradiation
- Sponsor
- Ossium Health, Inc.
Leukemia, Myeloid, Acute
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
The present trial will be performed to determine the MTD and to evaluate the efficacy of BI 2536 in the treatment of elderly patients with relapsed or refractory AML.
- Trial name
- NCT00701766
- Testing
- BI 2536
- Where
- 9 sites in Austria, Germany
- Volunteers
- 71 people
- Sponsor
- Boehringer Ingelheim
Acute Myeloid Leukemia
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in sequence with standard treatments before a…
- Trial name
- NCT02614560
- Testing
- Fludarabine, Melphalan, vadastuximab talirine
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- Seagen Inc.
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
This is an open-label, Phase I study to determine the highest amount of the study drug, ON 01910.Na, that can be safety given to patients with high risk myelodysplastic syndromes (MDS) or refractory leukemias.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00854646
- Testing
- ON 01910.Na
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Traws Pharma, Inc.
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
This phase I trial is studying the safety and potential efficacy of infusing non-human leukocyte antigen (HLA) matched ex vivo expanded cord blood progenitors following treatment with clofarabine and cytarabine for patients with…
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01031368
- Testing
- cytarabine, clofarabine, filgrastim
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Nohla Therapeutics, Inc.
Acute Myeloid Leukemia (AML)
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
This phase Ⅰ study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed AML.
- Trial name
- NCT04402723
- Testing
- Donafenib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Leukemia, Myeloid, Acute
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients >= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive…
- Trial name
- NCT01721876
- Testing
- Volasertib, Cytarabine
- Where
- 122 sites in United States, Argentina and 23 more
- Volunteers
- 666 people
- Sponsor
- Boehringer Ingelheim
Acute Myeloid Leukemia
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
- Trial name
- NCT00528333
- Testing
- Lintuzumab (SGN-33), Low dose cytarabine
- Where
- 20 sites in United States
- Volunteers
- 211 people
- Sponsor
- Seagen Inc.
ECG, Pharmacokinetics
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
This is a single-arm, open-label, Phase 4 study evaluating the effect of GO on the QTc, pharmacokinetics, safety, and immunogenicity of GO as a single-agent monotherapy in adult and pediatric patients with relapsed or refractory…
- Conditions
- ECG, Pharmacokinetics, Safety
- Trial name
- NCT03727750
- Testing
- Gemtuzumab Ozogamicin
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 51 people
- Sponsor
- Pfizer
Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.
- Trial name
- NCT03327727
- Testing
- Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 4 people
- Sponsor
- Vical
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Acute Myeloid Leukemia
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine and daunorubicin in induction, in combination…
- Trial name
- NCT03850535
- Testing
- Idasanutlin, Cytarabine, Daunorubicin
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
B-cell Lymphoma, Acute Myeloid Leukemia
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
- Conditions
- B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06820268
- Testing
- XS-04 tablet
- Where
- 4 sites in China
- Volunteers
- 168 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer, Lung Cancer
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used…
- Conditions
- Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer
- Trial name
- NCT05974150
- Testing
- Web based survey
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Carevive Systems, Inc.
Acute Myeloid Leukemia
Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)
This is a Phase II trial conducted at multiple centers for evaluation of the pharmacodynamic activity and the overall response rate contributed by the combination agents of GTI-2040 and High Dose Cytarabine (HiDAC) in Refractory…
- Trial name
- NCT00565058
- Testing
- GTI-2040
- Where
- 7 sites in United States
- Volunteers
- 27 people
- Sponsor
- Aptose Biosciences Inc.
Acute Myeloid Leukemia
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
This is a Phase I, open-label, non-randomized, multicenter study to evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in previously untreated elderly patients with AML who…
- Trial name
- NCT03483948
- Testing
- HMPL-523, Azacitidine
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hutchison Medipharma Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.